Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity
Jiaxing He, Bingyu Huang, Kun Zhang, Mubiao Liu, Tianmin Xu, Jiaxing He, Bingyu Huang, Kun Zhang, Mubiao Liu, Tianmin Xu
Abstract
Genome regions that do not for code for proteins are generally transcribed into long non-coding RNAs. Growing evidence reveals that lncRNAs, defined as transcripts longer than 200 nucleotides, are commonly deregulated in cervical malignancies. New sequencing technologies have revealed a complete picture of the composition of the human transcriptome. LncRNAs perform diverse functions at transcriptional, translation, and post-translational levels through interactions with proteins, RNA and DNA. In the past decade, studies have shown that lncRNAs participate in the pathogenesis of many diseases, including cervical cancer. Hence, illuminating the roles of lncRNA will improve our understanding of cervical cancer. In this work, we summarize the current knowledge on lncRNAs in cervical cancer. We describe the emerging roles of lncRNAs in cervical cancer, particularly in cancer progression, metastasis, treatment resistance, HPV regulation, and metabolic reprogramming. The great promises of lncRNAs as potential biomarkers for cervical cancer diagnosis and prognosis are also discussed. We discuss current technologies used to target lncRNAs and thus control cancers, such as antisense oligonucleotides, CRISPR-Cas9, and exosomes. Overall, we show that lncRNAs hold great potentials as therapeutic agents and innovative biomarkers. Finally, further clinical research is necessary to advance our understanding of the therapeutic value of lncRNAs in cervical cancer.
Keywords: Cervical cancer; Epithelial-to-mesenchymal; Human papillomavirus; Therapeutic opportunities; lncRNA; microRNA.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no competing interests.
Copyright © 2020. Published by Elsevier Masson SAS.
Source: PubMed